Clinical Trial Update: Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating oral QLT091001 in adults with impaired dark adaptation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impaired Dark Adaptation

Drugs mentioned

• QLT091001 (retinoid)

Snippet

Sponsor: QLT Inc. | Conditions: Impaired Dark Adaptation | Phase 2 | Status: COMPLETED